Obstructive sleep apnea as a potential contributor to stuttering priapism: a case series

Background: The etiologies and management of patients with stuttering priapism remain somewhat perplexing, with most cases being idiopathic, however the underlying molecular basis for some causes, such as sickle cell disease, is believed to be due to the depletion of nitric oxide and resulting dysfunction of cyclic guanosine monophosphate (cGMP)-induced vasodilation of corporal smooth muscle. We propose a potential mechanism for stuttering priapism in patients with obstructive sleep apnea (OSA) and report on patients with OSA and success (or lack thereof) in their management at our institution. Cases: A brief query of the institution’s electronic medical record was performed from 01 January 2023 to 01 January 2024 through the use of an existing institutional review board approval, and a total of three patients were identified who were treated for stuttering/recurrent priapism with a pre-existing diagnosis of OSA or with high suspicion of OSA. Some of these patients noted a reduction in priapism episodes with improved control of their OSA through means such as continuous positive airway pressure (CPAP) machines. Conclusions: Obstructive sleep apnea may be a possible risk factor for stuttering priapism and thus should be considered by the clinician. It shares a similar mechanism to that of sickle cell disease’s role in priapism: nitric oxide depletion and PDE5 (phosphodiesterase 5) downregulation resulting in intermittent, unregulated smooth muscle relaxation through non-nitric oxide pathways; thus, this should be evaluated by the clinician.

Priapism; Recurrent; Stuttering; Nitric oxide; Erection; Erectile dysfunction; Sleep apnea

[1] Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. Priapism: pathogenesis, epidemiology, and management. The Journal of Sexual Medicine. 2010; 7: 476–500.

[2] Witt MA, Goldstein I, de Tejada IS, Greenfield A, Krane RJ. Traumatic laceration of intracavernosal arteries: the pathophysiology of nonischemic, high flow, arterial priapism. The Journal of Urology. 1990; 143: 129–132.

[3] Rodríguez J, Cuadrado JM, Frances A, Franco E. High-flow priapism as a complication of a veno-occlusive priapism: two case reports. International Journal of Impotence Research. 2006; 18: 215–217.

[4] Bertolotto M, Ciampalini S, Martingano P, Mucelli FP. High-flow priapism complicating ischemic priapism following iatrogenic laceration of the dorsal artery during a Winter procedure. Journal of Clinical Ultrasound. 2009; 37: 61–64.

[5] Adeyoju AB, Olujohungbe ABK, Morris J, Yardumian A, Bareford D, Akenova A, et al. Priapism in sickle-cell disease; incidence, risk factors and complications—an international multicentre study. BJU International. 2002; 90: 898–902.

[6] Wong R, Bal DS, Chung D, Yafi F, Lumbiganon S, Patel P. Sleep-related painful erections: a survey-based analysis of patient-reported experiences with diagnosis and management. International Journal of Impotence Research. 2025; 37: 436–442.

[7] Roizenblatt M, Figueiredo MS, Cançado RD, Pollack-Filho F, de Almeida Santos Arruda MM, Vicari P, et al. Priapism is associated with sleep hypoxemia in sickle cell disease. The Journal of Urology. 2012; 188: 1245–1251.

[8] Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102: 1661–1666.

[9] Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. Pharmacology & Therapeutics. 2013; 38: 407–419.

[10] Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Reviews. 2007; 21: 37–47.

[11] Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology. 2006; 67: 1043–1048.

[12] Weiss JW, Liu Y, Li X, Ji ES. Nitric oxide and obstructive sleep apnea. Respiratory Physiology & Neurobiology. 2012; 184: 192–196.

[13] Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Medicine Reviews. 2017; 34: 70–81.

[14] Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. The Lancet Respiratory Medicine. 2019; 7: 687–698.

[15] Eastwood PR, Malhotra A, Palmer LJ, Kezirian EJ, Horner RL, Ip MS, et al. Obstructive sleep apnoea: from pathogenesis to treatment: current controversies and future directions. Respirology. 2010; 15: 587–595.

[16] Chung F, Subramanyam R, Liao P, Sasaki E, Shapiro C, Sun Y. High STOP-Bang score indicates a high probability of obstructive sleep apnoea. British Journal of Anaesthesia. 2012; 108: 768–775.

[17] Amra B, Rahmati B, Soltaninejad F, Feizi A. Screening questionnaires for obstructive sleep apnea: an updated systematic review. Oman Medical Journal. 2018; 33: 184–192.

[18] Wu ZH, Tang Y, Niu X, Sun HY. The role of nitric oxide (NO) levels in patients with obstructive sleep apnea-hypopnea syndrome: a meta-analysis. Sleep and Breathing. 2021; 25: 9–16.

[19] Kavdia M, Popel AS. Contribution of nNOS- and eNOS-derived NO to microvascular smooth muscle NO exposure. Journal of Applied Physiology. 2004; 97: 293–301.

[20] Culla B, Guida G, Brussino L, Tribolo A, Cicolin A, Sciascia S, et al. Increased oral nitric oxide in obstructive sleep apnoea. Respiratory Medicine. 2010; 104: 316–320.

[21] Alonso-Fernández A, García-Río F, Arias MA, Hernanz Á, Peña M de la, Piérola J, et al. Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnoea: a randomised trial. Thorax. 2009; 64: 581–586.

[22] Noda A, Nakata S, Koike Y, Miyata S, Kitaichi K, Nishizawa T, et al. Continuous positive airway pressure improves daytime baroreflex sensitivity and nitric oxide production in patients with moderate to severe obstructive sleep apnea syndrome. Hypertension Research. 2007; 30: 669–676.

[23] Ip MSM, Lam B, Chan LY, Zheng L, Tsang KWT, Fung PCW, et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. American Journal of Respiratory and Critical Care Medicine. 2000; 162: 2166–2171.

[24] Budweiser S, Enderlein S, Jörres RA, Hitzl AP, Wieland WF, Pfeifer M, et al. Sleep apnea is an independent correlate of erectile and sexual dysfunction. The Journal of Sexual Medicine. 2009; 6: 3147–3157.

[25] Cantone E, Massanova M, Crocetto F, Barone B, Esposito F, Arcaniolo D, et al. The relationship between obstructive sleep apnoea and erectile dysfunction: an underdiagnosed link? A prospective cross‐sectional study. Andrologia. 2022; 54: e14504.

[26] Javaheri S, Caref EB, Chen E, Tong KB, Abraham WT. Sleep apnea testing and outcomes in a large cohort of medicare beneficiaries with newly diagnosed heart failure. American Journal of Respiratory and Critical Care Medicine. 2011; 183: 539–546.

[27] Dahm P, Rao DS, Donatucci CF. Antiandrogens in the treatment of priapism. Urology. 2002; 59: 138.

[28] Mwamukonda KB, Chi T, Shindel AW, Lue TF. Androgen blockade for the treatment of high-flow priapism. The Journal of Sexual Medicine. 2010; 7: 2532–2537.

[29] Kovac JR, Mak SK, Garcia MM, Lue TF. A pathophysiology-based approach to the management of early priapism. Asian Journal of Andrology. 2013; 15: 20–26.